Research Overview
The carnitine shuttle
Long-chain fatty acids activated as acyl-CoA in the cytosol cannot cross the inner mitochondrial membrane unaided. Carnitine palmitoyltransferase 1 transfers the acyl group to carnitine, a translocase carries the acylcarnitine inward, and CPT2 restores the acyl-CoA in the matrix. CPT1 activity is inhibited by malonyl-CoA, which is what links this transport step to the cell's fed and fasted signaling state and makes it a favored point of study in fatty-acid oxidation research.
Carnitine availability questions
Whether adding carnitine to a system with adequate carnitine changes oxidation flux is a genuinely open question in the literature. In carnitine-deficient states the answer is clear; in replete tissue the shuttle is generally not the limiting step, so studies commonly include baseline carnitine and acylcarnitine profiling before drawing conclusions.
Acylcarnitine profiling
- Tandem mass spectrometry panels of short-, medium- and long-chain acylcarnitines
- Ratios used as indicators of incomplete beta-oxidation
- Free carnitine to acylcarnitine ratio as a marker of carnitine sufficiency
Methyl-donor components
Methionine, choline and B12 carry the same roles they have in the MIC and B12 base: SAM synthesis, phosphatidylcholine formation for hepatic lipid export, and cofactor supply for methionine synthase and methylmalonyl-CoA mutase. Choline-deficiency models of hepatic steatosis remain the clearest demonstration of that component's role, since removing choline alone reproducibly drives triglyceride accumulation in rodent liver.
Stability of the mixture
Component-level control
With five components present, only designs that include single-component arms can attribute an observed change to a particular ingredient. Mixture-level studies describe the formulation as a whole and should be reported that way.
